Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Operating Leases (2018 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Operating Leases for 7 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 23.43% to $8.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.5 million, a 23.43% decrease, with the full-year FY2025 number at $8.5 million, down 23.43% from a year prior.
  • Operating Leases was $8.5 million for Q4 2025 at Cartesian Therapeutics, down from $8.7 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $14.9 million in Q2 2024 to a low of $3.2 million in Q4 2022.
  • A 5-year average of $9.5 million and a median of $9.0 million in 2021 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: tumbled 62.78% in 2022, then soared 174.66% in 2023.
  • Cartesian Therapeutics' Operating Leases stood at $8.6 million in 2021, then crashed by 62.78% to $3.2 million in 2022, then skyrocketed by 174.66% to $8.8 million in 2023, then rose by 26.67% to $11.1 million in 2024, then decreased by 23.43% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Operating Leases are $8.5 million (Q4 2025), $8.7 million (Q3 2025), and $9.6 million (Q2 2025).